Login to Your Account

Northwest's DCVax-L Adds UK Sites in Phase III GBM Program

By Catherine Shaffer
Staff Writer

Friday, August 24, 2012
The Medicines and Healthcare Products Regulatory Agency of the UK approved a 300-patient Phase III trial of Northwest Biotherapeutics Inc.'s DCVax-L for glioblastoma multiforme (GBM). Phase III is in full swing in the U.S., at 41 clinical sites, but Northwest seeks to expand the trial to international sites, starting in the UK, stating it will save several years' time by not carrying out separate U.S. and European trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription